<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085655</url>
  </required_header>
  <id_info>
    <org_study_id>NKT-SYSUCC-2013</org_study_id>
    <nct_id>NCT02085655</nct_id>
  </id_info>
  <brief_title>PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma</brief_title>
  <official_title>PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huiqiang Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's&#xD;
      lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the&#xD;
      efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with&#xD;
      gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria The eligibility criteria were pathologically confirmed, previously&#xD;
      untreated or refractory/relapsed ENKTL as defined by the World Health Organization&#xD;
      classification; age≥18 years; Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
      0-2; at least one measurable lesion; adequate haematologic function (haemoglobin &gt; 9.0 g/l,&#xD;
      absolute neutrophil count &gt; 1500/ml, platelets &gt; 75,000/l), hepatic function (total serum&#xD;
      bilirubin ≤ 1.5 times the upper limit of normal, alanine aminotransferase and aspartate&#xD;
      aminotransferase ≤ 2.5 times the upper limit of normal), renal function (serum creatinine ≤&#xD;
      1.5 mg/dl, creatinine clearance ≥ 50 ml/min); normal coagulation function and&#xD;
      electrocardiogram results. Prior chemotherapy and radiotherapy should have been completed &gt;4&#xD;
      weeks earlier, willingness to provide written informed consent. Stage was defined according&#xD;
      to the Ann Arbor system. The Sun Yat-Sen University Cancer Centre Research Ethics Board&#xD;
      approved this study before subjects were enrolled.&#xD;
&#xD;
      Treatment PA-Gemox dosages were as follows: days 1 and 8, 30-min intravenous infusion of 1000&#xD;
      mg/m2 gemcitabine; day 1, 2-h intravenous infusion of 130 mg/m2 oxaliplatin; day 1, deep&#xD;
      intramuscular injection of 2500 U/m2 PEG-ASP at two different sites. The regimen was repeated&#xD;
      every 3 weeks for a maximum of six cycles. Stage IE/IIE patients underwent four cycles&#xD;
      induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD.&#xD;
      Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per&#xD;
      daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.&#xD;
      Refractory/relapsed patients underwent at least two cycles treatments unless there was&#xD;
      disease progression or unacceptable side effects, or withdrawal of patient consent.&#xD;
      Autologous haematopoietic stem cell transplantation (AHSCT) was recommended after they&#xD;
      achieved CR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Outcome Measure</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Study group increase 15% 2-year PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/Adverse Event Outcome Measure</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of Participants with Serious and Non-Serious Adverse Events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy Outcome Measure</measure>
    <time_frame>Up to 36 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <other_name>Oncaspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>AspaMetDex regimen group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100-200mg, PO, after chemotherapy</description>
    <arm_group_label>PEG-ASP+Gemox regimen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. pathologically confirmed, previously untreated or refractory/relapsed ENKTL as defined&#xD;
             by the World Health Organization classification;&#xD;
&#xD;
          2. age≥18 years;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;&#xD;
&#xD;
          4. at least one measurable lesion;&#xD;
&#xD;
          5. adequate haematologic function (haemoglobin &gt; 9.0 g/l, absolute neutrophil count &gt;&#xD;
             1500/ml, platelets &gt; 75,000/l),&#xD;
&#xD;
          6. adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of&#xD;
             normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper&#xD;
             limit of normal),&#xD;
&#xD;
          7. adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50&#xD;
             ml/min);&#xD;
&#xD;
          8. normal coagulation function and electrocardiogram results.&#xD;
&#xD;
          9. Prior chemotherapy and radiotherapy should have been completed &gt;4 weeks earlier,&#xD;
&#xD;
         10. willingness to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HuiQiang Huang</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HuiQiang Huang</last_name>
    <phone>86-020-87343350</phone>
    <email>huanghq@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology, Sun Yat-sen University Cancer Center,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HuiQiang Huang</last_name>
      <phone>86-020-87343350</phone>
      <email>huanghq@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huiqiang Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Extranodal NK/T-cell lymphoma</keyword>
  <keyword>PA-Gemox regimen</keyword>
  <keyword>thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

